NeuroOne Medical Technologies Corporation has entered a collaboration with the University of Minnesota Medical School’s Department of Neurology to advance a study evaluating next-generation epilepsy therapies using the company’s sEEG-based platform. The program, led by Professor and Epilepsy Division Director Sandipan Pati, MD, will test novel therapeutics delivered locally into specific brain regions involved in sustaining seizures with the goal of improving clinical efficacy and lowering systemic toxicity and off-target effects.
‘Localized intracerebral delivery of therapeutics represents an important emerging direction for improving precision in epilepsy treatment while minimizing systemic side effects,’ said Dr. Pati, who also serves as Director of the University of Minnesota Physicians MINCEP® Epilepsy Care Program. The research focuses on preclinical studies evaluating the feasibility, safety, and physiological effects of intracerebral drug infusion using minimally invasive intracranial platforms, including ultra-thin electrode-based systems designed to reduce tissue disruption.
According to Dr. Pati, current clinical practice uses FDA-cleared intracranial electrodes for recording brain activity and performing therapeutic interventions such as stimulation and ablation. The new research aims to better understand how targeted delivery influences seizure networks and brain-body interactions. ‘If successful, this approach may help inform future translational efforts towards a human study to develop more precise and individualized therapies for patients with epilepsy,’ he explained.
Dave Rosa, President and CEO of NeuroOne, stated that ‘The University of Minnesota is at the forefront of next-generation epilepsy research.’ He added that ‘As we continue advancing our preclinical drug delivery platform toward commercial readiness, we believe this collaboration will support development of a first-in-human study utilizing our technology for intracerebral treatment of epileptic seizures.’ Rosa emphasized that if successful, this approach could redefine seizure care and establish a new era of precision brain-directed therapy.
The collaboration is expected to begin in large animal models and, if primary objectives are met, progress to human studies shortly thereafter. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families, including Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. For more information about the company’s technology platform, visit nmtc1.com.
This development represents a significant step toward more targeted neurological treatments that could potentially reduce hospitalizations, lower healthcare costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions. The research builds upon existing FDA-cleared technologies while exploring new applications for drug delivery directly to affected brain regions, potentially creating more effective treatments for epilepsy patients who have not responded to conventional therapies.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is NeuroOne Partners with University of Minnesota to Advance Targeted Epilepsy Treatment Platform.